Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Sue Pedersen
University of Calgary, Calgary, Canada
Dr Sue D Pedersen is a specialist in endocrinology and metabolism, a certified American Board of Obesity Medicine (ABOM) diplomate, and a clinical lecturer at the University of Calgary, Canada. Her clinical endocrinology practice is at the C-ENDO Diabetes & Endocrinology Clinic in Calgary. read more
Dr Pedersen is heavily involved in obesity and type 2 diabetes research. She is principal investigator, national lead investigator, and/or global panel member for several studies of obesity and diabetes pharmacotherapy, and has authored dozens of peer-reviewed publications.
Dr Pedersen is the lead author on the Pharmacotherapy chapter of the 2020 and 2022 Canadian Obesity Clinical Practice Guidelines, which is formally endorsed by The Obesity Society (TOS), Obesity Medicine Association (OMA), European Association for the Study of Obesity (EASO), and many other obesity organizations. She is also a member of the Expert Committee for the Diabetes Canada guidelines as a co-author of the Weight Management chapter. She has a public information website for healthcare providers and patients about obesity and diabetes with over 3.2 million hits to date (www.drsue.ca), and a podcast (www.dishingthescience.com).
Dr Susan Pedersen discloses: Independent contractor relationship from Abbott, AstraZeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, Eisai, GlaxoSmithKline, Lilly, Novo Nordisk and Pfizer. Advisory board or panel fees from Abbott, AstraZeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, GlaxoSmithKline, Lilly, Novo Nordisk and Pfizer. Consultant fees from Abbott, AstraZeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, GlaxoSmithKline, Lilly, Novo Nordisk and Pfizer. Grants/research support from AstraZeneca, Lilly, Novo Nordisk, Pfizer, Prometic and Sanofi. Speaker’s Bureau fees from Abbott, AstraZeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, GlaxoSmithKline, Lilly and Novo Nordisk.
Dr Donna Ryan
Pennington Biomedical Research Center, Baton Rouge, LA, USA
Dr Donna Ryan is professor emerita at Pennington Biomedical in Baton Rouge, LA, USA, where she leads the obesity and nutrition clinical research programmes. read more
She was an investigator on POUNDS Lost, Look AHEAD, Diabetes Prevention Program (DPP), Dietary Approaches to Stop Hypertension (DASH) and many other studies on the health benefits of weight loss by diet, lifestyle intervention and medications. Her personal research studied improving primary care management of obesity. She has been an active member and former president of The Obesity Society (North America) and World Obesity Federation. Dr Ryan served as co-chair of the SELECT Steering Committee and is a member of the Data Safety Monitoring Boards for setmelanotide, retatrutide and CIN-110-112.
Dr Ryan has more than 300 publications; is a frequent speaker on obesity and diabetes treatments; and remains an active consultant and advisor to companies developing drugs, devices, lifestyle programmes and medical approaches to obesity management.
Dr Donna Ryan discloses: Advisory board or panel fees from Altimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Biohaven, Calibrate, Carmot/Roche, CINRx, Currax, Epitomee; Fractyl, Gila, Lilly, Nestle, Novo Nordisk, Pfizer, Regeneron, Structure Therapeutics and Wondr Health, Zealand. Consultant fees from eMedd and Scientific Intake (Relationship Terminated). Speaker’s Bureau fees from Lilly and Novo Nordisk. Stock/shareholder (self-managed) fees from Calibrate, Epitomee; Roman, Scientific Intake and Xeno Bioscience (Relationships Terminated).
Prof. Carel le Roux
University College Dublin, Dublin, Ireland
Prof. Carel le Roux graduated from medical school in Pretoria South Africa, and completed his specialist training in metabolic medicine at St Bartholomew’s Hospitals and the Hammersmith Hospitals. read more
He obtained his PhD from Imperial College London, where he later took up a faculty position. He moved to University College Dublin for the chair in Chemical Pathology and Metabolic Medicine and he is now a director of the Metabolic Medicine Group. He also holds the position of professor of metabolic medicine at Ulster University and extraordinary professor of chemical pathology at University of Pretoria.
Prof. le Roux currently coordinates an Innovative Medicine Initiative project on obesity. He previously received the Irish Research Council Researcher of the Year award, a President of Ireland Young Researcher Award, the Irish Research Council Laureate Award, a Clinician Scientist Award from the National Institute Health Research in the UK, and a Wellcome Trust Clinical Research Fellowship for his work on how the gut talks to the brain.
Prof. Carel le Roux discloses: Grant/research support from: Anabio and Irish Research Council, Health Research Board, Science Foundation Ireland. Advisory board/consulting fees from Altimmune, Amgen, Arrowhead, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GI Dynamics, Gila Pharmaceuticals, Herbalife, Irish Life Health, Irish Society for Nutrition and Metabolism, Johnson & Johnson, Keyron, Novo Nordisk and Roche. Speaker’s bureau fees from Boehringer Ingelheim, Currax Pharmaceuticals, Eli Lilly, Herbalife, Johnson & Johnson, Novo Nordisk and Rhythm Pharmaceuticals. Other financial or non-financial interests fees from Beyond BMI, Co-owner Obesity Clinics and My Best Weight.
